No statistical significance was detected at week 12.[ 20 ] In another study, there was a nonsignificant trend suggesting that HLA-Cw6-POS patients were more likely to respond to adalimumab.[ 21 ] In this study, it was found that HLA-Cw6 was not predictive of response to adalimumab In our study, the rate of response from infliximab in HLA-Cw6-POS patients was 75%, whereas this ratio was 77.8% in HLA-Cw6 - NEG patients ( P = 1.00).
1
—
—